MARK2 and glioblastoma: AKT is a serine/threonine kinase in and large scale genomic analysis of GBM, has been demonstrated that this molecule is mutated in the majority of GBMs and inhibition of AKT an attractive target for GBM therapy (A McDowell et al., 2011).